[
    {
        "text": "(upbeat music)",
        "start": 3.627,
        "duration": 2.583
    },
    {
        "text": "Yeah first, I'd like to thank c&en",
        "start": 8.952,
        "duration": 2.298
    },
    {
        "text": "for giving me the chance to be part of the Talented Twelve.",
        "start": 11.25,
        "duration": 3.11
    },
    {
        "text": "And for everyone who wrote the really nice articles,",
        "start": 14.36,
        "duration": 2.13
    },
    {
        "text": "and organizing this really nice symposium.",
        "start": 16.49,
        "duration": 2.38
    },
    {
        "text": "And also I'd like to congratulate everyone else",
        "start": 18.87,
        "duration": 3.09
    },
    {
        "text": "in the Talented Twelve.",
        "start": 21.96,
        "duration": 1.915
    },
    {
        "text": "As the baby of this group,",
        "start": 23.875,
        "duration": 1.517
    },
    {
        "text": "I am super-duper humbled to be amongst all of you.",
        "start": 25.392,
        "duration": 3.603
    },
    {
        "text": "So first I'm gonna give you a little bit",
        "start": 28.995,
        "duration": 3.295
    },
    {
        "text": "of background about me.",
        "start": 32.29,
        "duration": 1.95
    },
    {
        "text": "So, I was born in Maryland",
        "start": 34.24,
        "duration": 3.19
    },
    {
        "text": "to two Ghanaian-American immigrants,",
        "start": 37.43,
        "duration": 2.605
    },
    {
        "text": "and I spent my first two years there.",
        "start": 40.035,
        "duration": 2.858
    },
    {
        "text": "At the age of two, I moved to Ghana,",
        "start": 42.893,
        "duration": 3.147
    },
    {
        "text": "where my parents are from,",
        "start": 46.04,
        "duration": 1.27
    },
    {
        "text": "and lived there for 10 years.",
        "start": 47.31,
        "duration": 1.713
    },
    {
        "text": "That was a great experience.",
        "start": 49.872,
        "duration": 1.257
    },
    {
        "text": "I got to learn about my culture.",
        "start": 51.129,
        "duration": 2.081
    },
    {
        "text": "I learned my language.",
        "start": 53.21,
        "duration": 1.16
    },
    {
        "text": "I had the privilege of attending a really nice,",
        "start": 54.37,
        "duration": 2.13
    },
    {
        "text": "a really great school",
        "start": 56.5,
        "duration": 1.2
    },
    {
        "text": "that really gave me a good background in math sciences,",
        "start": 57.7,
        "duration": 4.575
    },
    {
        "text": "and also really got to, essentially",
        "start": 62.275,
        "duration": 4.375
    },
    {
        "text": "gain a lot of interest in certain things",
        "start": 66.65,
        "duration": 2.0
    },
    {
        "text": "that I didn't realize would shape my future,",
        "start": 68.65,
        "duration": 2.284
    },
    {
        "text": "including chemical biology.",
        "start": 70.934,
        "duration": 2.596
    },
    {
        "text": "I then moved to Virginia,",
        "start": 73.53,
        "duration": 2.547
    },
    {
        "text": "and attended middle school and high school,",
        "start": 76.077,
        "duration": 2.946
    },
    {
        "text": "here in Virginia.",
        "start": 79.981,
        "duration": 0.833
    },
    {
        "text": "And there you could find me either on the tennis court",
        "start": 80.814,
        "duration": 2.816
    },
    {
        "text": "or I also gained a really nice interest",
        "start": 83.63,
        "duration": 2.8
    },
    {
        "text": "in math and science.",
        "start": 86.43,
        "duration": 1.39
    },
    {
        "text": "While I'd, you know, get things marked wrong",
        "start": 87.82,
        "duration": 3.255
    },
    {
        "text": "for spelling it the British way.",
        "start": 91.075,
        "duration": 1.375
    },
    {
        "text": "Math and science is the same everywhere",
        "start": 92.45,
        "duration": 2.267
    },
    {
        "text": "and that's great.",
        "start": 94.717,
        "duration": 1.504
    },
    {
        "text": "So after high school,",
        "start": 96.221,
        "duration": 2.037
    },
    {
        "text": "because of my interest in science,",
        "start": 98.258,
        "duration": 2.641
    },
    {
        "text": "I went to Cornell University,",
        "start": 100.899,
        "duration": 2.341
    },
    {
        "text": "and I'd often kinda teeter-totter",
        "start": 103.24,
        "duration": 2.0
    },
    {
        "text": "between whether I wanted to be a chemistry major,",
        "start": 106.339,
        "duration": 1.654
    },
    {
        "text": "a biology major.",
        "start": 108.92,
        "duration": 1.36
    },
    {
        "text": "We didn't quite have a chemical biology focus at that time.",
        "start": 110.28,
        "duration": 1.85
    },
    {
        "text": "I ended up being a chem major",
        "start": 112.13,
        "duration": 1.809
    },
    {
        "text": "and took a lot of biology classes.",
        "start": 113.939,
        "duration": 1.781
    },
    {
        "text": "And I think my interest has kinda stayed that path since.",
        "start": 115.72,
        "duration": 3.073
    },
    {
        "text": "Outside of coursework,",
        "start": 118.793,
        "duration": 2.017
    },
    {
        "text": "I actually first joined a lab just for work study.",
        "start": 120.81,
        "duration": 4.649
    },
    {
        "text": "I figured I was science major,",
        "start": 125.459,
        "duration": 2.181
    },
    {
        "text": "I might as well join a lab,",
        "start": 127.64,
        "duration": 1.69
    },
    {
        "text": "and see what that's about.",
        "start": 129.33,
        "duration": 2.14
    },
    {
        "text": "I started off in a microbiology lab first washing dishes",
        "start": 131.47,
        "duration": 2.92
    },
    {
        "text": "of course, as often many of us do,",
        "start": 134.39,
        "duration": 1.864
    },
    {
        "text": "and then moved on",
        "start": 136.254,
        "duration": 1.656
    },
    {
        "text": "to actually performing some really nice gene mapping",
        "start": 137.91,
        "duration": 3.49
    },
    {
        "text": "in this ciliate here.",
        "start": 141.4,
        "duration": 2.357
    },
    {
        "text": "And then halfway through my undergraduate career,",
        "start": 143.757,
        "duration": 4.153
    },
    {
        "text": "I met Manuel Aregulian",
        "start": 147.91,
        "duration": 1.39
    },
    {
        "text": "who was doing some really interesting work",
        "start": 149.3,
        "duration": 2.943
    },
    {
        "text": "with plant biology, specifically, medicinal plant biology.",
        "start": 152.243,
        "duration": 3.307
    },
    {
        "text": "And I feel like anyone who has",
        "start": 155.55,
        "duration": 2.07
    },
    {
        "text": "like a maybe African background",
        "start": 157.62,
        "duration": 1.56
    },
    {
        "text": "has always like a grandma",
        "start": 160.04,
        "duration": 1.52
    },
    {
        "text": "who has some plant that does something,",
        "start": 161.56,
        "duration": 1.776
    },
    {
        "text": "and I thought that was super interesting",
        "start": 163.336,
        "duration": 1.546
    },
    {
        "text": "to bring kinda science to that.",
        "start": 164.882,
        "duration": 1.708
    },
    {
        "text": "So I spent a summer in the Dominican Republic",
        "start": 166.59,
        "duration": 2.72
    },
    {
        "text": "studying medicinal plants,",
        "start": 169.31,
        "duration": 1.84
    },
    {
        "text": "and then came back to Cornell",
        "start": 171.15,
        "duration": 1.21
    },
    {
        "text": "and then studied solidago canadensis",
        "start": 172.36,
        "duration": 2.741
    },
    {
        "text": "which was thought to have some",
        "start": 175.101,
        "duration": 1.599
    },
    {
        "text": "anti-diabetic therapeutic potential.",
        "start": 177.539,
        "duration": 2.311
    },
    {
        "text": "After this, I definitely loved research a lot more",
        "start": 179.85,
        "duration": 2.783
    },
    {
        "text": "than I thought I did.",
        "start": 182.633,
        "duration": 1.557
    },
    {
        "text": "And I wasn't entirely sure what to do",
        "start": 184.19,
        "duration": 2.191
    },
    {
        "text": "after undergraduate,",
        "start": 186.381,
        "duration": 2.969
    },
    {
        "text": "my undergraduate career.",
        "start": 189.35,
        "duration": 1.6
    },
    {
        "text": "So I decided to participate in a PREP program.",
        "start": 190.95,
        "duration": 3.3
    },
    {
        "text": "So the PREP programs are funded by the NIH.",
        "start": 194.25,
        "duration": 3.87
    },
    {
        "text": "And they are specifically",
        "start": 198.12,
        "duration": 0.9
    },
    {
        "text": "for underrepresented minorities in science.",
        "start": 199.956,
        "duration": 2.534
    },
    {
        "text": "And there are a number of institutions.",
        "start": 202.49,
        "duration": 1.99
    },
    {
        "text": "I performed mine at Mount Sinai in New York City.",
        "start": 204.48,
        "duration": 3.539
    },
    {
        "text": "There, I was mentored outside the lab by Terry Krulwich,",
        "start": 208.019,
        "duration": 3.331
    },
    {
        "text": "who was an amazing scientist and an amazing mentor.",
        "start": 211.35,
        "duration": 2.23
    },
    {
        "text": "And she was really,",
        "start": 213.58,
        "duration": 2.94
    },
    {
        "text": "she was really important for me in helping me",
        "start": 216.52,
        "duration": 2.14
    },
    {
        "text": "kind of craft a graduate school application,",
        "start": 218.66,
        "duration": 1.96
    },
    {
        "text": "which I didn't really have much experience with",
        "start": 220.62,
        "duration": 2.0
    },
    {
        "text": "or have family who really knew anything about.",
        "start": 222.62,
        "duration": 2.19
    },
    {
        "text": "So she was really important to me in that regard.",
        "start": 224.81,
        "duration": 2.21
    },
    {
        "text": "And in terms of research while I was there,",
        "start": 227.02,
        "duration": 2.737
    },
    {
        "text": "I took a slight turn off,",
        "start": 229.757,
        "duration": 2.673
    },
    {
        "text": "and did some homology modeling and virtual screening.",
        "start": 232.43,
        "duration": 2.847
    },
    {
        "text": "I didn't have any background at all",
        "start": 235.277,
        "duration": 2.283
    },
    {
        "text": "in any type of computational work,",
        "start": 237.56,
        "duration": 2.5
    },
    {
        "text": "yet Abner took me on,",
        "start": 240.06,
        "duration": 1.293
    },
    {
        "text": "and he thought it'd be cool for me to also learn about this.",
        "start": 242.317,
        "duration": 2.423
    },
    {
        "text": "So I spent the first six months of my year there",
        "start": 244.74,
        "duration": 3.05
    },
    {
        "text": "kind of learning homology modeling,",
        "start": 247.79,
        "duration": 1.47
    },
    {
        "text": "learning the scripts behind that.",
        "start": 249.26,
        "duration": 1.77
    },
    {
        "text": "And then for my last six months,",
        "start": 251.03,
        "duration": 1.58
    },
    {
        "text": "Abner kind of put me in a lot of collaborations",
        "start": 252.61,
        "duration": 2.09
    },
    {
        "text": "with different scientists,",
        "start": 254.7,
        "duration": 1.601
    },
    {
        "text": "which one, exposed me to a lot of science,",
        "start": 256.301,
        "duration": 1.259
    },
    {
        "text": "and two, helped me learn how to kind of craft a story",
        "start": 257.56,
        "duration": 3.0
    },
    {
        "text": "for a publication.",
        "start": 260.56,
        "duration": 0.96
    },
    {
        "text": "And it ended up in two nice publications",
        "start": 261.52,
        "duration": 1.75
    },
    {
        "text": "with a couple of collaborators,",
        "start": 263.27,
        "duration": 2.365
    },
    {
        "text": "which was great.",
        "start": 265.635,
        "duration": 0.833
    },
    {
        "text": "I then decided to pursue a PhD,",
        "start": 266.468,
        "duration": 2.713
    },
    {
        "text": "after my great experience at Mount Sinai.",
        "start": 269.181,
        "duration": 3.099
    },
    {
        "text": "Luckily I got into a number of programs,",
        "start": 272.28,
        "duration": 2.66
    },
    {
        "text": "and decided to choose Yale's pharmacology program",
        "start": 274.94,
        "duration": 3.18
    },
    {
        "text": "due to number of reasons,",
        "start": 278.12,
        "duration": 2.09
    },
    {
        "text": "including some really cool programs they had,",
        "start": 280.21,
        "duration": 1.8
    },
    {
        "text": "such as the medical research scholars program,",
        "start": 282.01,
        "duration": 2.41
    },
    {
        "text": "which kind of helped bridge the gap",
        "start": 284.42,
        "duration": 2.02
    },
    {
        "text": "between the bench and medicine.",
        "start": 286.44,
        "duration": 2.0
    },
    {
        "text": "And also because of their really strong chemical biology,",
        "start": 288.44,
        "duration": 2.419
    },
    {
        "text": "you know, labs that they had.",
        "start": 290.859,
        "duration": 3.682
    },
    {
        "text": "Specifically, you know, the work of Craig Crews.",
        "start": 294.541,
        "duration": 4.409
    },
    {
        "text": "So I actually for the first time met Craig",
        "start": 298.95,
        "duration": 2.25
    },
    {
        "text": "during, essentially rotation talks",
        "start": 301.2,
        "duration": 3.04
    },
    {
        "text": "where each professor is given five minutes to kind of,",
        "start": 304.24,
        "duration": 3.66
    },
    {
        "text": "to sell their work to incoming grad students",
        "start": 307.9,
        "duration": 3.04
    },
    {
        "text": "for possible rotation.",
        "start": 310.94,
        "duration": 1.26
    },
    {
        "text": "And when I heard Craig talk,",
        "start": 312.2,
        "duration": 2.099
    },
    {
        "text": "I just could not stop smiling.",
        "start": 314.299,
        "duration": 0.833
    },
    {
        "text": "I thought the work was so, so cool.",
        "start": 315.132,
        "duration": 1.448
    },
    {
        "text": "And luckily I ended up rotating and joining the lab.",
        "start": 316.58,
        "duration": 3.52
    },
    {
        "text": "So what was so cool about Craig's work,",
        "start": 320.1,
        "duration": 2.86
    },
    {
        "text": "first, I'm going to take a few steps back",
        "start": 322.96,
        "duration": 1.67
    },
    {
        "text": "to just telling you about the life of a protein.",
        "start": 324.63,
        "duration": 2.91
    },
    {
        "text": "So as many of you probably know,",
        "start": 327.54,
        "duration": 2.21
    },
    {
        "text": "DNA is transcribed into RNA,",
        "start": 329.75,
        "duration": 2.06
    },
    {
        "text": "which is translated into proteins.",
        "start": 331.81,
        "duration": 1.88
    },
    {
        "text": "And proteins then go on to perform",
        "start": 333.69,
        "duration": 2.88
    },
    {
        "text": "their intended function.",
        "start": 336.57,
        "duration": 1.565
    },
    {
        "text": "Once a protein's performed its intended function,",
        "start": 338.135,
        "duration": 3.455
    },
    {
        "text": "it comes to the end of its life,",
        "start": 341.59,
        "duration": 2.3
    },
    {
        "text": "it has its own half-life.",
        "start": 343.89,
        "duration": 1.77
    },
    {
        "text": "Its death is a little bit more, you know,",
        "start": 345.66,
        "duration": 2.17
    },
    {
        "text": "regulated than our death is,",
        "start": 347.83,
        "duration": 1.57
    },
    {
        "text": "in that proteins are tagged with ubiquitin,",
        "start": 349.4,
        "duration": 2.6
    },
    {
        "text": "which leads to the recruitment by the proteasome,",
        "start": 352.0,
        "duration": 3.75
    },
    {
        "text": "and to their degradation.",
        "start": 355.75,
        "duration": 1.85
    },
    {
        "text": "So in order to target disease causing genes,",
        "start": 357.6,
        "duration": 2.61
    },
    {
        "text": "there are lots of different, you know,",
        "start": 360.21,
        "duration": 2.362
    },
    {
        "text": "modalities to go after them.",
        "start": 362.572,
        "duration": 1.638
    },
    {
        "text": "To target DNA,",
        "start": 364.21,
        "duration": 1.11
    },
    {
        "text": "There are gene therapies or CRISPr,",
        "start": 365.32,
        "duration": 1.75
    },
    {
        "text": "which is still in the works right now.",
        "start": 368.156,
        "duration": 1.064
    },
    {
        "text": "mRNA's, RNAi's are also things that are in development",
        "start": 369.22,
        "duration": 4.2
    },
    {
        "text": "and at the protein level,",
        "start": 373.42,
        "duration": 1.4
    },
    {
        "text": "there are small molecules and antibodies",
        "start": 374.82,
        "duration": 1.67
    },
    {
        "text": "that are also used.",
        "start": 376.49,
        "duration": 1.58
    },
    {
        "text": "However, what Craig talked about was something that used",
        "start": 378.07,
        "duration": 2.41
    },
    {
        "text": "kind of this last part of the protein's lifecycle",
        "start": 380.48,
        "duration": 2.809
    },
    {
        "text": "and looked at using ubiquitination",
        "start": 383.289,
        "duration": 3.811
    },
    {
        "text": "and proteasomal degradation as a possible therapy.",
        "start": 387.1,
        "duration": 3.9
    },
    {
        "text": "So, what he calls his tool is a PROTAC.",
        "start": 391.0,
        "duration": 3.14
    },
    {
        "text": "So PROteolysis Targeting Chimeras,",
        "start": 394.14,
        "duration": 2.24
    },
    {
        "text": "and they consist of a protein of interest targeting ligand,",
        "start": 396.38,
        "duration": 3.94
    },
    {
        "text": "a short chemical linker,",
        "start": 400.32,
        "duration": 1.63
    },
    {
        "text": "and an E3 ligase recruiting ligand,",
        "start": 401.95,
        "duration": 2.02
    },
    {
        "text": "which is essentially the degradation machinery",
        "start": 403.97,
        "duration": 1.9
    },
    {
        "text": "that allows for proteins to be ubiquitinated and degraded.",
        "start": 405.87,
        "duration": 2.563
    },
    {
        "text": "And PROTACs work by what we call event-driven pharmacology,",
        "start": 408.433,
        "duration": 5.0
    },
    {
        "text": "where they simply bring together the protein of interest",
        "start": 413.529,
        "duration": 3.581
    },
    {
        "text": "into close proximity with that E3 ligase,",
        "start": 417.11,
        "duration": 2.57
    },
    {
        "text": "which then allows for protein,",
        "start": 419.68,
        "duration": 1.51
    },
    {
        "text": "the protein to be ubiquitinated and degraded.",
        "start": 421.19,
        "duration": 3.23
    },
    {
        "text": "In addition, it's event-driven",
        "start": 424.42,
        "duration": 1.5
    },
    {
        "text": "because it's a catalytic process,",
        "start": 425.92,
        "duration": 1.74
    },
    {
        "text": "and that one small molecule,",
        "start": 427.66,
        "duration": 2.373
    },
    {
        "text": "or one small molecule PROTAC",
        "start": 430.033,
        "duration": 1.68
    },
    {
        "text": "can induce the ubiquitination and degradation",
        "start": 431.713,
        "duration": 1.739
    },
    {
        "text": "of more than one protein at a time.",
        "start": 433.452,
        "duration": 2.039
    },
    {
        "text": "One protein molecule at a time.",
        "start": 435.491,
        "duration": 2.372
    },
    {
        "text": "So once I learned about this technology,",
        "start": 439.153,
        "duration": 2.377
    },
    {
        "text": "I wanted to use it for difficult disease causing proteins.",
        "start": 441.53,
        "duration": 2.879
    },
    {
        "text": "And I worked on a number of different projects in the lab,",
        "start": 444.409,
        "duration": 3.651
    },
    {
        "text": "but the one that really took off",
        "start": 448.06,
        "duration": 2.251
    },
    {
        "text": "and ended up kind of being my PhD baby,",
        "start": 450.311,
        "duration": 1.589
    },
    {
        "text": "was my work on BRAF.",
        "start": 451.9,
        "duration": 1.77
    },
    {
        "text": "So BRAF is a kinase,",
        "start": 453.67,
        "duration": 1.52
    },
    {
        "text": "and what kinases do",
        "start": 455.19,
        "duration": 1.04
    },
    {
        "text": "is that they phosphorolate target proteins,",
        "start": 457.132,
        "duration": 1.398
    },
    {
        "text": "which is another type of post-translational modification.",
        "start": 458.53,
        "duration": 2.74
    },
    {
        "text": "And that leads to a number of downstream effects,",
        "start": 461.27,
        "duration": 2.42
    },
    {
        "text": "such as activation,",
        "start": 463.69,
        "duration": 1.31
    },
    {
        "text": "changes in the localization of a protein,",
        "start": 465.0,
        "duration": 2.13
    },
    {
        "text": "or even changing the different interaction partners",
        "start": 467.13,
        "duration": 2.17
    },
    {
        "text": "with proteins.",
        "start": 469.3,
        "duration": 0.853
    },
    {
        "text": "And these small, more localized effects",
        "start": 471.255,
        "duration": 1.795
    },
    {
        "text": "lead to different things, such as, you know,",
        "start": 473.05,
        "duration": 1.72
    },
    {
        "text": "inducing other proteins to be synthesized,",
        "start": 474.77,
        "duration": 2.42
    },
    {
        "text": "changing cell division, motility, growth,",
        "start": 477.19,
        "duration": 2.31
    },
    {
        "text": "or also changing, you know, your entire metabolism.",
        "start": 479.5,
        "duration": 3.05
    },
    {
        "text": "So BRAF is specifically a kinase",
        "start": 482.55,
        "duration": 2.27
    },
    {
        "text": "that is mutated in a number of cancers.",
        "start": 484.82,
        "duration": 3.59
    },
    {
        "text": "8% of all cancers.",
        "start": 488.41,
        "duration": 1.6
    },
    {
        "text": "The most common BRAF mutation is BRAF V600E.",
        "start": 490.01,
        "duration": 3.02
    },
    {
        "text": "So the valine mutated",
        "start": 493.03,
        "duration": 1.761
    },
    {
        "text": "and essentially causes an upregulation",
        "start": 494.791,
        "duration": 3.939
    },
    {
        "text": "of BRAF's kinase activity",
        "start": 498.73,
        "duration": 2.823
    },
    {
        "text": "leading to its activation and uncontrolled cell growth,",
        "start": 501.553,
        "duration": 2.637
    },
    {
        "text": "primarily in a number of cancers, including melanoma.",
        "start": 504.19,
        "duration": 3.203
    },
    {
        "text": "So essentially misregulation of BRAF is an issue.",
        "start": 507.393,
        "duration": 4.699
    },
    {
        "text": "However, due to its prevalence of V600E specifically,",
        "start": 512.092,
        "duration": 3.259
    },
    {
        "text": "there have been small molecule inhibitors",
        "start": 515.351,
        "duration": 3.309
    },
    {
        "text": "that have been developed.",
        "start": 518.66,
        "duration": 1.25
    },
    {
        "text": "Primarily the first one developed in 2011 is Vemurafenib.",
        "start": 521.553,
        "duration": 2.536
    },
    {
        "text": "And the way it works",
        "start": 524.089,
        "duration": 1.421
    },
    {
        "text": "is by occupancy driven pharmacology,",
        "start": 526.39,
        "duration": 2.37
    },
    {
        "text": "where it kind of takes the place of its normal substrate ATP",
        "start": 528.76,
        "duration": 3.16
    },
    {
        "text": "and inhibits the protein's function.",
        "start": 531.92,
        "duration": 2.0
    },
    {
        "text": "And small molecule inhibitors are really great therapies",
        "start": 533.92,
        "duration": 2.4
    },
    {
        "text": "and they worked really well for oncology,",
        "start": 536.32,
        "duration": 2.615
    },
    {
        "text": "but one issue with them, unfortunately,",
        "start": 538.935,
        "duration": 2.055
    },
    {
        "text": "is that resistance does form to them.",
        "start": 540.99,
        "duration": 2.883
    },
    {
        "text": "And in the case of Vemurafenib,",
        "start": 543.873,
        "duration": 2.157
    },
    {
        "text": "this occurs between six to eight months.",
        "start": 546.03,
        "duration": 2.92
    },
    {
        "text": "And mechanisms of resistance include upregulation",
        "start": 548.95,
        "duration": 3.97
    },
    {
        "text": "of the kinase itself,",
        "start": 552.92,
        "duration": 1.892
    },
    {
        "text": "things that completely bypass the kinase",
        "start": 554.812,
        "duration": 2.538
    },
    {
        "text": "and allow for the same function to occur",
        "start": 557.35,
        "duration": 2.85
    },
    {
        "text": "without using that kinase,",
        "start": 560.2,
        "duration": 1.65
    },
    {
        "text": "or additional mutations.",
        "start": 561.85,
        "duration": 1.6
    },
    {
        "text": "And these are acquired resistance mechanisms",
        "start": 563.45,
        "duration": 2.49
    },
    {
        "text": "to BRAF V600E.",
        "start": 565.94,
        "duration": 1.863
    },
    {
        "text": "And beyond that even, so beyond the V600E,",
        "start": 568.89,
        "duration": 3.255
    },
    {
        "text": "this one point mutation there,",
        "start": 572.145,
        "duration": 1.268
    },
    {
        "text": "as more cancers and tumors are being sequenced,",
        "start": 575.084,
        "duration": 1.596
    },
    {
        "text": "we've identified several more.",
        "start": 576.68,
        "duration": 1.74
    },
    {
        "text": "So there are two, a Class 2 BRAF inhibitors,",
        "start": 578.42,
        "duration": 2.78
    },
    {
        "text": "Two Class 2 BRAF.",
        "start": 581.2,
        "duration": 1.43
    },
    {
        "text": "A BRAF in Class 3, which are really interesting,",
        "start": 582.63,
        "duration": 2.07
    },
    {
        "text": "in that they're kinase dead.",
        "start": 584.7,
        "duration": 1.41
    },
    {
        "text": "But all these additional classes have also been shown",
        "start": 586.11,
        "duration": 2.46
    },
    {
        "text": "to drive different cancers.",
        "start": 588.57,
        "duration": 1.4
    },
    {
        "text": "And unfortunately,",
        "start": 589.97,
        "duration": 1.053
    },
    {
        "text": "Vemurafenib is intrinsically resistant to both of these.",
        "start": 591.921,
        "duration": 2.203
    },
    {
        "text": "So in general,",
        "start": 594.124,
        "duration": 2.116
    },
    {
        "text": "BRAF is a kinase and they are inhibitors",
        "start": 596.24,
        "duration": 3.13
    },
    {
        "text": "for one specific mutation,",
        "start": 599.37,
        "duration": 1.2
    },
    {
        "text": "but there really is a need for additional therapies",
        "start": 600.57,
        "duration": 2.46
    },
    {
        "text": "to target this.",
        "start": 603.03,
        "duration": 1.01
    },
    {
        "text": "And this is kind of where our project came in.",
        "start": 604.04,
        "duration": 2.74
    },
    {
        "text": "So, in collaboration with a really great,",
        "start": 606.78,
        "duration": 2.89
    },
    {
        "text": "really great chemist in the lab, Saul,",
        "start": 609.67,
        "duration": 2.54
    },
    {
        "text": "we synthesized and designed a number of different PROTACs.",
        "start": 612.21,
        "duration": 3.44
    },
    {
        "text": "I think we ended up designing about 30,",
        "start": 615.65,
        "duration": 2.3
    },
    {
        "text": "and this is our lead at the end,",
        "start": 617.95,
        "duration": 2.11
    },
    {
        "text": "which included Vemurafenib as our BRAF recruiting ligand,",
        "start": 620.06,
        "duration": 4.741
    },
    {
        "text": "a sharp chemical linker,",
        "start": 624.801,
        "duration": 2.599
    },
    {
        "text": "Pearson based linker,",
        "start": 627.4,
        "duration": 0.96
    },
    {
        "text": "and then the VHL ligand.",
        "start": 628.36,
        "duration": 1.593
    },
    {
        "text": "So the first thing we did was to evaluate our PROTACs",
        "start": 631.17,
        "duration": 3.29
    },
    {
        "text": "in fiberblast cells",
        "start": 634.46,
        "duration": 1.11
    },
    {
        "text": "that expressed a number of different mutations",
        "start": 636.417,
        "duration": 2.32
    },
    {
        "text": "that are, that had been seen in clinic.",
        "start": 638.737,
        "duration": 3.473
    },
    {
        "text": "And what we saw was that with treatment of our PROTAC,",
        "start": 642.21,
        "duration": 3.63
    },
    {
        "text": "we saw a dose dependent decrease in BRAF levels.",
        "start": 645.84,
        "duration": 3.06
    },
    {
        "text": "So degradation of the mutant BRAF,",
        "start": 648.9,
        "duration": 3.08
    },
    {
        "text": "which was really great.",
        "start": 651.98,
        "duration": 1.701
    },
    {
        "text": "But even more interesting was that our PROTAC",
        "start": 653.681,
        "duration": 2.32
    },
    {
        "text": "was able to spare wild type BRAF.",
        "start": 656.001,
        "duration": 2.749
    },
    {
        "text": "So we're able to selectively target",
        "start": 658.75,
        "duration": 1.87
    },
    {
        "text": "only the mutant form of the protein,",
        "start": 660.62,
        "duration": 1.84
    },
    {
        "text": "and completely spare the normal functioning protein,",
        "start": 662.46,
        "duration": 2.52
    },
    {
        "text": "which is really great",
        "start": 664.98,
        "duration": 0.833
    },
    {
        "text": "in terms of when you design a drug,",
        "start": 665.813,
        "duration": 2.385
    },
    {
        "text": "'cause you really want to increase that therapeutic index",
        "start": 668.198,
        "duration": 1.302
    },
    {
        "text": "and which decreases the chance of toxicity.",
        "start": 669.5,
        "duration": 3.73
    },
    {
        "text": "So we went on to test these in cancer cells",
        "start": 673.23,
        "duration": 2.22
    },
    {
        "text": "and saw similar results",
        "start": 675.45,
        "duration": 1.38
    },
    {
        "text": "in inhibition of the pathway.",
        "start": 676.83,
        "duration": 2.18
    },
    {
        "text": "And those results made us hopeful to test these in,",
        "start": 679.01,
        "duration": 3.75
    },
    {
        "text": "in a xenograph model in mice.",
        "start": 682.76,
        "duration": 1.82
    },
    {
        "text": "And we found that a 10 day treatment",
        "start": 684.58,
        "duration": 2.7
    },
    {
        "text": "caused a really nice tumor regression",
        "start": 687.28,
        "duration": 2.15
    },
    {
        "text": "in the cell line that is a Class 2 BRAF,",
        "start": 689.43,
        "duration": 3.911
    },
    {
        "text": "which is insensitive to Vemurafenib,",
        "start": 693.341,
        "duration": 3.42
    },
    {
        "text": "as I said before.",
        "start": 696.761,
        "duration": 1.019
    },
    {
        "text": "So in general here,",
        "start": 697.78,
        "duration": 1.32
    },
    {
        "text": "we're able to take essentially",
        "start": 699.1,
        "duration": 1.943
    },
    {
        "text": "a warhead that is insensitive",
        "start": 701.043,
        "duration": 1.715
    },
    {
        "text": "to one mutant and turn it into a PROTAC,",
        "start": 702.758,
        "duration": 2.783
    },
    {
        "text": "which is able to induce degradation",
        "start": 705.541,
        "duration": 2.719
    },
    {
        "text": "of something that has no therapy right now,",
        "start": 708.26,
        "duration": 2.1
    },
    {
        "text": "which was really wonderful to see.",
        "start": 710.36,
        "duration": 1.59
    },
    {
        "text": "And we did this in collaboration with the Rosen lab,",
        "start": 711.95,
        "duration": 2.56
    },
    {
        "text": "which were a great set of BRAF biologists to work with.",
        "start": 714.51,
        "duration": 3.483
    },
    {
        "text": "So in summary,",
        "start": 718.98,
        "duration": 1.39
    },
    {
        "text": "why are PROTACs so great,",
        "start": 720.37,
        "duration": 1.1
    },
    {
        "text": "and why was I so excited to work with them?",
        "start": 721.47,
        "duration": 1.78
    },
    {
        "text": "One, because of their catalytic mechanism of action,",
        "start": 723.25,
        "duration": 2.9
    },
    {
        "text": "they're able to target overexpressed,",
        "start": 726.15,
        "duration": 2.33
    },
    {
        "text": "proteins that are overexpressed.",
        "start": 728.48,
        "duration": 1.23
    },
    {
        "text": "So you don't have to use more drug",
        "start": 729.71,
        "duration": 1.64
    },
    {
        "text": "to overcome overexpression.",
        "start": 731.35,
        "duration": 1.83
    },
    {
        "text": "In addition,",
        "start": 733.18,
        "duration": 1.19
    },
    {
        "text": "you don't necessarily need something",
        "start": 734.37,
        "duration": 1.15
    },
    {
        "text": "to completely inhibit a protein.",
        "start": 735.52,
        "duration": 1.78
    },
    {
        "text": "You just kind of need a binder",
        "start": 737.3,
        "duration": 1.59
    },
    {
        "text": "to tag your proteins",
        "start": 738.89,
        "duration": 1.88
    },
    {
        "text": "in order to recruit them,",
        "start": 740.77,
        "duration": 1.468
    },
    {
        "text": "you know, or in order to induce degradation.",
        "start": 742.238,
        "duration": 2.712
    },
    {
        "text": "And in our projects,",
        "start": 744.95,
        "duration": 0.833
    },
    {
        "text": "we're able to show that.",
        "start": 745.783,
        "duration": 1.735
    },
    {
        "text": "We're able to selectively do this",
        "start": 747.518,
        "duration": 0.922
    },
    {
        "text": "with acquired and intrinsic resistance mechanisms to BRAF.",
        "start": 748.44,
        "duration": 3.195
    },
    {
        "text": "However of course,",
        "start": 751.635,
        "duration": 1.095
    },
    {
        "text": "things that completely bypass BRAF",
        "start": 752.73,
        "duration": 1.849
    },
    {
        "text": "we're unable to target.",
        "start": 754.579,
        "duration": 1.478
    },
    {
        "text": "In addition, PROTACs are really poised",
        "start": 756.057,
        "duration": 3.573
    },
    {
        "text": "to kind of,",
        "start": 759.63,
        "duration": 0.833
    },
    {
        "text": "and degraders in general,",
        "start": 760.463,
        "duration": 1.818
    },
    {
        "text": "are poised to expand kind of that druggable space.",
        "start": 762.281,
        "duration": 1.758
    },
    {
        "text": "So right now therapies, unfortunately,",
        "start": 764.039,
        "duration": 1.716
    },
    {
        "text": "only touch a small quarter of disease causing proteins,",
        "start": 765.755,
        "duration": 3.681
    },
    {
        "text": "and due to the mechanism of action,",
        "start": 769.436,
        "duration": 2.514
    },
    {
        "text": "if these were helpful,",
        "start": 771.95,
        "duration": 2.364
    },
    {
        "text": "that would be able to kind of tag these undruggable,",
        "start": 774.314,
        "duration": 2.926
    },
    {
        "text": "quote on quote proteins,",
        "start": 777.24,
        "duration": 1.11
    },
    {
        "text": "and induce degradation.",
        "start": 778.35,
        "duration": 1.54
    },
    {
        "text": "And that's kind of what I'm still excited about,",
        "start": 779.89,
        "duration": 2.22
    },
    {
        "text": "and what I'm still working on right now",
        "start": 782.11,
        "duration": 1.42
    },
    {
        "text": "at Monte Rosa Therapeutics,",
        "start": 783.53,
        "duration": 1.67
    },
    {
        "text": "but taking a slightly different path,",
        "start": 785.2,
        "duration": 2.52
    },
    {
        "text": "which is still in the same space.",
        "start": 787.72,
        "duration": 1.65
    },
    {
        "text": "So the way molecular glues work is that",
        "start": 789.37,
        "duration": 1.58
    },
    {
        "text": "they first bind your E3 ligase of interest.",
        "start": 790.95,
        "duration": 2.328
    },
    {
        "text": "And then only in the presence of these,",
        "start": 793.278,
        "duration": 1.832
    },
    {
        "text": "are you able to bind your disease causing protein",
        "start": 795.11,
        "duration": 2.77
    },
    {
        "text": "and induce similar proteasome-mediated degradation.",
        "start": 797.88,
        "duration": 2.177
    },
    {
        "text": "However, molecular glues tend to be smaller,",
        "start": 800.057,
        "duration": 5.0
    },
    {
        "text": "drug-like molecules,",
        "start": 805.2,
        "duration": 1.33
    },
    {
        "text": "and for that reason,",
        "start": 806.53,
        "duration": 0.833
    },
    {
        "text": "I thought to maybe be a little bit easier",
        "start": 807.363,
        "duration": 1.867
    },
    {
        "text": "in terms of getting accepted into the clinic.",
        "start": 809.23,
        "duration": 1.97
    },
    {
        "text": "And in addition, it doesn't need a druggable pocket",
        "start": 811.2,
        "duration": 2.66
    },
    {
        "text": "on your disease causing protein,",
        "start": 813.86,
        "duration": 1.41
    },
    {
        "text": "which also poises it to kind of touch,",
        "start": 815.27,
        "duration": 2.203
    },
    {
        "text": "to better reach undruggable proteins.",
        "start": 817.473,
        "duration": 3.547
    },
    {
        "text": "So with that, I would like to thank",
        "start": 821.02,
        "duration": 2.39
    },
    {
        "text": "everyone who has been on my journey",
        "start": 823.41,
        "duration": 1.68
    },
    {
        "text": "from Cornell, to the Schlessinger Lab, to the PREP program.",
        "start": 825.09,
        "duration": 4.02
    },
    {
        "text": "Everyone at the Crews lab who I interacted with,",
        "start": 829.11,
        "duration": 2.86
    },
    {
        "text": "it was a great, great learning experience.",
        "start": 831.97,
        "duration": 2.13
    },
    {
        "text": "My collaborators at the Rosen Lab,",
        "start": 834.1,
        "duration": 1.97
    },
    {
        "text": "my thesis committee,",
        "start": 836.07,
        "duration": 1.09
    },
    {
        "text": "and everyone at Monte Rosa,",
        "start": 837.16,
        "duration": 1.513
    },
    {
        "text": "Dom, Sharon, who work with me now.",
        "start": 840.376,
        "duration": 1.894
    },
    {
        "text": "And last but not least, of course,",
        "start": 842.27,
        "duration": 2.267
    },
    {
        "text": "I'd like to thank my family",
        "start": 844.537,
        "duration": 1.258
    },
    {
        "text": "and my partner Bomboy",
        "start": 845.795,
        "duration": 1.344
    },
    {
        "text": "for being a huge support system to me,",
        "start": 847.139,
        "duration": 1.391
    },
    {
        "text": "and helping me reach where I am today.",
        "start": 848.53,
        "duration": 2.1
    },
    {
        "text": "With that, I'll take any questions.",
        "start": 850.63,
        "duration": 1.75
    },
    {
        "text": "Thank you so much Shanique.",
        "start": 853.42,
        "duration": 2.33
    },
    {
        "text": "I was wondering what,",
        "start": 855.75,
        "duration": 1.389
    },
    {
        "text": "what happened to your PROTAC?",
        "start": 857.139,
        "duration": 2.459
    },
    {
        "text": "what are the next steps for it?",
        "start": 859.598,
        "duration": 1.702
    },
    {
        "text": "The one you developed.",
        "start": 861.3,
        "duration": 1.1
    },
    {
        "text": "So, unfortunately I'm no longer in the lab,",
        "start": 863.55,
        "duration": 2.149
    },
    {
        "text": "but I know that I hear that, like, you know,",
        "start": 865.699,
        "duration": 2.24
    },
    {
        "text": "we still have interest in trying",
        "start": 867.939,
        "duration": 1.917
    },
    {
        "text": "a couple of different cancer types",
        "start": 869.856,
        "duration": 4.234
    },
    {
        "text": "that we didn't necessarily touch on",
        "start": 874.09,
        "duration": 1.711
    },
    {
        "text": "in my project.",
        "start": 875.801,
        "duration": 1.469
    },
    {
        "text": "So that's definitely ongoing right now.",
        "start": 877.27,
        "duration": 2.42
    },
    {
        "text": "Yeah, in the lab.",
        "start": 879.69,
        "duration": 0.883
    },
    {
        "text": "Okay.",
        "start": 881.46,
        "duration": 1.557
    },
    {
        "text": "Thank you so much.",
        "start": 883.017,
        "duration": 1.402
    },
    {
        "text": "(upbeat music)",
        "start": 884.419,
        "duration": 2.667
    }
]